Article
Cell‐free circulating tumour DNA as a liquid biopsy in breast cancer
17 Dec 2015
Abstract excerpt
Recent developments in massively parallel sequencing and digital genomic techniques support the clinical validity of cell-free circulating tumour DNA (ctDNA) as a 'liquid biopsy' in human cancer. In breast cancer, ctDNA detected in plasma can be used to non-invasively scan tumour genomes and quantify tumour burden. The applications for ctDNA in plasma include identifying actionable genomic alterations, monitoring...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
